;PMID: 118814 ;source_file_1011.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..50] = [t:0..50] ;1)sentence:[e:56..174] = [t:56..174] ;2)section:[e:178..197] = [t:178..197] ;3)section:[e:201..272] = [t:201..272] ;4)sentence:[e:276..466] = [t:276..466] ;5)sentence:[e:467..618] = [t:467..618] ;6)sentence:[e:619..711] = [t:619..711] ;7)sentence:[e:712..787] = [t:712..787] ;8)sentence:[e:788..843] = [t:788..843] ;9)sentence:[e:844..996] = [t:844..996] ;10)sentence:[e:997..1062] = [t:997..1062] ;11)sentence:[e:1063..1117] = [t:1063..1117] ;12)section:[e:1121..1164] = [t:1121..1164] ;section 0 Span:0..50 ;C R Seances Acad Sci D. 1979 Nov 5;289(11):777-80. (SEC (FRAG (NNP:[0..1] C) (NNP:[2..3] R) (NNP:[4..11] Seances) (NNP:[12..16] Acad) (NNP:[17..20] Sci) (NNP:[21..23] D.) (CD:[24..28] 1979) (NNP:[29..32] Nov) (CC:[33..39] 5;289-LRB-) (CD:[39..41] 11) (-RRB-:[41..42] -RRB-) (CD:[42..46] :777) (::[46..47] -) (CD:[47..49] 80) (.:[49..50] .))) ;sentence 1 Span:56..174 ;[Demonstration of "hydroxylase" and "epoxide hydrase" activities in ;preparations of nucleoli isolated from rat liver] ;[75..86]:substance:"hydroxylase" ;[93..108]:substance:"epoxide hydrase" (SENT (NP-HLN (-LRB-:[56..57] -LSB-) (NP (NN:[57..70] Demonstration)) (PP (IN:[71..73] of) (NP (NP (``:[74..75] ") (NN:[75..86] hydroxylase) ('':[86..87] ") (NML-1 (-NONE-:[87..87] *P*))) (CC:[88..91] and) (NP (``:[92..93] ") (NN:[93..100] epoxide) (NN:[101..108] hydrase) ('':[108..109] ") (NML-1 (NNS:[110..120] activities))))) (PP (IN:[121..123] in) (NP (NP (NNS:[124..136] preparations)) (PP (IN:[138..140] of) (NP (NP (NNS:[141..149] nucleoli)) (VP (VBN:[150..158] isolated) (NP (-NONE-:[158..158] *)) (PP (IN:[159..163] from) (NP (NN:[164..167] rat) (NN:[168..173] liver)))))))) (-RRB-:[173..174] -RSB-))) ;section 2 Span:178..197 ;[Article in French] (SEC (FRAG (NN:[178..186] -LSB-Article) (IN:[187..189] in) (JJ:[190..196] French) (NNS:[196..197] -RSB-))) ;section 3 Span:201..272 ;Lafarge-Frayssinet C, Alexandrov K, Dansette P, Guerry R, Frayssinet C. (SEC (FRAG (NNP:[201..208] Lafarge) (::[208..209] -) (NNP:[209..219] Frayssinet) (NNP:[220..221] C) (,:[221..222] ,) (NNP:[223..233] Alexandrov) (NNP:[234..235] K) (,:[235..236] ,) (NNP:[237..245] Dansette) (NNP:[246..247] P) (,:[247..248] ,) (NNP:[249..255] Guerry) (NNP:[256..258] R,) (NNP:[259..269] Frayssinet) (NNP:[270..272] C.))) ;sentence 4 Span:276..466 ;Aryl hydrocarbon hydroxylase (AHH) activity and epoxyde hydrase (EH) activity ; have been found in Rat liver nucleoli obtained from untreated (C) and ;methylcholanthrene (MC) pretreated Rats. ;[276..304]:substance:"Aryl hydrocarbon hydroxylase" ;[306..309]:substance:"AHH" ;[324..339]:substance:"epoxyde hydrase" ;[341..343]:substance:"EH" ;[426..444]:substance:"methylcholanthrene" ;[446..448]:substance:"MC" (SENT (S (NP-SBJ-2 (NP (NML (NML (NN:[276..280] Aryl) (NN:[281..292] hydrocarbon) (NN:[293..304] hydroxylase)) (NML (-LRB-:[305..306] -LRB-) (NN:[306..309] AHH) (-RRB-:[309..310] -RRB-))) (NN:[311..319] activity)) (CC:[320..323] and) (NP (NML (NML (NN:[324..331] epoxyde) (NN:[332..339] hydrase)) (NML (-LRB-:[340..341] -LRB-) (NN:[341..343] EH) (-RRB-:[343..344] -RRB-))) (NN:[345..353] activity))) (VP (VBP:[355..359] have) (VP (VBN:[360..364] been) (VP (VBN:[365..370] found) (NP-2 (-NONE-:[370..370] *)) (PP-LOC (IN:[371..373] in) (NP (NP (NN:[374..377] Rat) (NN:[378..383] liver) (NNS:[384..392] nucleoli)) (VP (VBN:[393..401] obtained) (NP (-NONE-:[401..401] *)) (PP (IN:[402..406] from) (NP (NP (NML (NML (JJ:[407..416] untreated)) (NML (-LRB-:[417..418] -LRB-) (NN:[418..419] C) (-RRB-:[419..420] -RRB-))) (NML-1 (-NONE-:[420..420] *P*))) (CC:[421..424] and) (NP (ADJP (NML (NML (NN:[426..444] methylcholanthrene)) (NML (-LRB-:[445..446] -LRB-) (NN:[446..448] MC) (-RRB-:[448..449] -RRB-))) (VBN:[450..460] pretreated)) (NML-1 (NNS:[461..465] Rats))))))))))) (.:[465..466] .))) ;sentence 5 Span:467..618 ;Electron microscopic observations of nucleolar preparations did not reveal ;significant contamination either by intact nuclei or by nuclear membranes. (SENT (S (NP-SBJ (NP (NN:[467..475] Electron) (JJ:[476..487] microscopic) (NNS:[488..500] observations)) (PP (IN:[501..503] of) (NP (JJ:[505..514] nucleolar) (NNS:[515..527] preparations)))) (VP (VBD:[528..531] did) (RB:[532..535] not) (VP (VB:[536..542] reveal) (NP (NP (JJ:[543..554] significant) (NN:[555..568] contamination)) (PP (CC:[569..575] either) (PP (IN:[576..578] by) (NP (JJ:[579..585] intact) (NNS:[587..593] nuclei))) (CC:[594..596] or) (PP (IN:[597..599] by) (NP (JJ:[600..607] nuclear) (NNS:[608..617] membranes))))))) (.:[617..618] .))) ;sentence 6 Span:619..711 ;Very low but detectable activity of NADPH cytochrome C reductase was found ;in the nucleoli. ;[655..660]:substance:"NADPH" ;[662..684]:substance:"cytochrome C reductase" (SENT (S (NP-SBJ-1 (NP (NP (ADJP (RB:[619..623] Very) (JJ:[624..627] low)) (NML-2 (-NONE-:[627..627] *P*))) (CC:[628..631] but) (NP (ADJP (JJ:[632..642] detectable)) (NML-2 (NN:[643..651] activity)))) (PP (IN:[652..654] of) (NP (NN:[655..660] NADPH) (NML (NN:[662..672] cytochrome) (NN:[673..674] C)) (NN:[675..684] reductase)))) (VP (VBD:[685..688] was) (VP (VBN:[689..694] found) (NP-1 (-NONE-:[694..694] *)) (PP-LOC (IN:[695..697] in) (NP (DT:[698..701] the) (NNS:[702..710] nucleoli))))) (.:[710..711] .))) ;sentence 7 Span:712..787 ;Nucleolar preparations revealed little AHH activity (12-18 pmoles/min/mg). ;[752..755]:substance:"AHH" ;[766..771]:quantitative-value:"12-18" ;[772..785]:quantitative-units:"pmoles/min/mg" (SENT (S (NP-SBJ (JJ:[712..721] Nucleolar) (NNS:[722..734] preparations)) (VP (VBD:[736..744] revealed) (NP (JJ:[745..751] little) (NN:[752..755] AHH) (NN:[756..764] activity) (PRN (-LRB-:[765..766] -LRB-) (NP (NP (QP (CD:[766..768] 12) (HYPH:[768..769] -) (CD:[769..771] 18)) (NNS:[772..778] pmoles)) (PP (SYM:[778..779] /) (NP (NN:[779..782] min))) (PP (SYM:[782..783] /) (NP (NN:[783..785] mg)))) (-RRB-:[785..786] -RRB-)))) (.:[786..787] .))) ;sentence 8 Span:788..843 ;AHH was inducible by MC in nuclei but not in nucleoli. ;[788..791]:substance:"AHH" ;[809..811]:substance:"MC" (SENT (S (NP-SBJ (NN:[788..791] AHH)) (VP (VP (VBD:[792..795] was) (NP-PRD (NP (JJ:[796..805] inducible)) (PP (IN:[806..808] by) (NP (NN:[809..811] MC))) (PP-LOC=1 (IN:[812..814] in) (NP (NNS:[816..822] nuclei))))) (CC:[823..826] but) (RB:[827..830] not) (VP (PP-LOC=1 (IN:[831..833] in) (NP (NNS:[834..842] nucleoli))))) (.:[842..843] .))) ;sentence 9 Span:844..996 ;The presence of EH in nucleoli was demonstrated with phenanthrene 9,10-oxide ;(550-620 pmoles/min/mg) and benzopyrene 4,5-oxide (92-116 pmoles/min/mg). ;[860..862]:substance:"EH" ;[898..921]:substance:"phenanthrene 9,10-oxide" ;[923..930]:quantitative-value:"550-620" ;[931..944]:quantitative-units:"pmoles/min/mg" ;[950..971]:substance:"benzopyrene 4,5-oxide" ;[974..980]:quantitative-value:"92-116" ;[981..994]:quantitative-units:"pmoles/min/mg" (SENT (S (NP-SBJ-1 (NP (DT:[844..847] The) (NN:[848..856] presence)) (PP (IN:[857..859] of) (NP (NN:[860..862] EH))) (PP-LOC (IN:[863..865] in) (NP (NNS:[866..874] nucleoli)))) (VP (VBD:[875..878] was) (VP (VBN:[879..891] demonstrated) (NP-1 (-NONE-:[891..891] *)) (PP (IN:[892..896] with) (NP (NP (NN:[898..910] phenanthrene) (NN:[911..921] 9,10-oxide) (PRN (-LRB-:[922..923] -LRB-) (NP (NP (QP (CD:[923..926] 550) (HYPH:[926..927] -) (CD:[927..930] 620)) (NNS:[931..937] pmoles)) (PP (SYM:[937..938] /) (NP (NN:[938..941] min))) (PP (SYM:[941..942] /) (NP (NN:[942..944] mg)))) (-RRB-:[944..945] -RRB-))) (CC:[946..949] and) (NP (NN:[950..961] benzopyrene) (NN:[962..971] 4,5-oxide) (PRN (-LRB-:[973..974] -LRB-) (NP (NP (QP (CD:[974..976] 92) (HYPH:[976..977] -) (CD:[977..980] 116)) (NNS:[981..987] pmoles)) (PP (SYM:[987..988] /) (NP (NN:[988..991] min))) (PP (SYM:[991..992] /) (NP (NN:[992..994] mg)))) (-RRB-:[994..995] -RRB-))))))) (.:[995..996] .))) ;sentence 10 Span:997..1062 ;These values were lower than those obtained using intact nuclei. (SENT (S (NP-SBJ (DT:[997..1002] These) (NNS:[1003..1009] values)) (VP (VBD:[1010..1014] were) (ADJP-PRD (ADJP (JJR:[1015..1020] lower)) (PP (IN:[1021..1025] than) (NP (NP (DT:[1026..1031] those)) (VP (VBN:[1032..1040] obtained) (NP (-NONE-:[1040..1040] *)) (S-MNR (NP-SBJ (-NONE-:[1040..1040] *)) (VP (VBG:[1041..1046] using) (NP (JJ:[1047..1053] intact) (NNS:[1055..1061] nuclei))))))))) (.:[1061..1062] .))) ;sentence 11 Span:1063..1117 ;The addition of TCPO (10(-4) M) inhibited EH activity. ;[1079..1083]:substance:"TCPO" ;[1085..1091]:quantitative-value:"10(-4)" ;[1092..1093]:quantitative-units:"M" ;[1105..1107]:substance:"EH" (SENT (S (NP-SBJ (NP (DT:[1063..1066] The) (NN:[1067..1075] addition)) (PP (IN:[1076..1078] of) (NP (NN:[1079..1083] TCPO) (PRN (-LRB-:[1084..1085] -LRB-) (NP (CD:[1085..1091] 10-LRB--4-RRB-) (NN:[1092..1093] M)) (-RRB-:[1093..1094] -RRB-))))) (VP (VBD:[1095..1104] inhibited) (NP (NN:[1105..1107] EH) (NN:[1108..1116] activity))) (.:[1116..1117] .))) ;section 12 Span:1121..1164 ;PMID: 118814 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1121..1125] PMID) (::[1125..1126] :) (CD:[1127..1133] 118814) (NN:[1134..1135] -LSB-) (NNP:[1135..1141] PubMed) (::[1142..1143] -) (NN:[1144..1151] indexed) (IN:[1152..1155] for) (NNP:[1156..1164] MEDLINE-RSB-)))